Mirae is building a new model for managing autoimmune disease and other complex chronic conditions, starting with inflammatory bowel disease. The company's conversational AI turns everyday patient input into structured, longitudinal insight, enabling earlier intervention and more informed treatment decisions. Developed in collaboration with researchers at the University of Oxford and designed for integration into clinical workflows, Mirae connects patient experience, clinical data, and peer-reviewed evidence into a continuous system of care. By extending the reach of specialty medicine beyond episodic visits, Mirae aims to make high-quality, data-driven care more consistent, more responsive, and more accessible across patient populations
Mirae
- Health
- London, United Kingdom
- £4m
- miraehealth.com
- Update Information
More venture news
- 3 Sept 2026

StrolllStrolll secures £4.3m in funding from Innovate UK and IW Capital for augmented reality neurorehabilitation
EquityHealth - 1 Sept 2026

HealfHealf secures funding led by SEMCAP Beauty & Wellness to expand its personalised wellbeing platform
EquityHealth - 11 Mar 2025

StrolllStrolll raises £10m Series A led by IW Capital to expand AR-based neurorehabilitation
Series AHealth
